{"id":938698,"date":"2026-02-20T09:26:01","date_gmt":"2026-02-20T14:26:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/"},"modified":"2026-02-20T09:26:01","modified_gmt":"2026-02-20T14:26:01","slug":"pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/","title":{"rendered":"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval"},"content":{"rendered":"

\nEnables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer
\n<\/h2>\n
\n

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The amendment includes PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and\/or metastatic head and neck cancer. Median overall survival (mOS) remains the trial\u2019s primary endpoint for full approval, consistent with the Company\u2019s prior regulatory dialogue and post-meeting communication following its Type C meeting with the U.S. Food and Drug Administration (\u201cFDA\u201d). Following the FDA’s standard 30-day wait period since filing of the amended protocol to the Investigational New Drug (IND) Application, without objection, the Company is proceeding with the amended protocol.<\/p>\n

\u201cIncluding PFS as an interim primary endpoint provides a potential pathway to shorten the duration of VERSATILE-003 and accelerate the timeline to regulatory submission, as well as making the trial more cost efficient,\u201d said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. \u201cSurvival and safety will continue to anchor full approval, and we remain confident in the path we\u2019ve outlined and in our commitment to advancing a promising targeted immunotherapy for the rapidly growing population of patients with HPV16-positive recurrent and\/or metastatic head and neck cancer.\u201d<\/p>\n

\n About PDS Biotechnology<\/strong>\n <\/p>\n

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech\u2019s lead investigational targeted immunotherapy PDS0101 (Versamune\u00ae<\/sup>\u00a0HPV) is being developed in combination with a standard-of-care immune checkpoint inhibitor, and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.<\/p>\n

For more information, please visit www.pdsbiotech.com<\/a><\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the \u201cCompany\u201d) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company\u2019s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cforecast,\u201d \u201cguidance\u201d, \u201coutlook\u201d and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company\u2019s ability to protect its intellectual property rights; the Company\u2019s anticipated capital requirements, including the Company\u2019s anticipated cash runway and the Company\u2019s current expectations regarding its plans for future equity financings; the Company\u2019s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company\u2019s operations or require the Company to relinquish rights to the Company\u2019s technologies or product candidates; the Company\u2019s limited operating history in the Company\u2019s current line of business, which makes it difficult to evaluate the Company\u2019s prospects, the Company\u2019s business plan or the likelihood of the Company\u2019s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0101 (Versamune\u00ae<\/sup>\u00a0HPV), PDS01ADC, PDS0103 (Versamune\u00ae<\/sup>\u00a0MUC1) and other Versamune\u00ae based product candidates; the future success of such trials; the successful implementation of the Company\u2019s research and development programs and collaborations, including any collaboration studies concerning PDS0101 (Versamune\u00ae<\/sup>\u00a0HPV), PDS01ADC, PDS0103 (Versamune\u00ae<\/sup>\u00a0MUC1) and other Versamune\u00ae<\/sup> based product candidates and the Company\u2019s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company\u2019s product candidates; the success, timing and cost of the Company\u2019s or its partners\u2019 ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company\u2019s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company\u2019s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.\u202f\u202f<\/p>\n

Versamune\u00ae<\/sup> is a registered trademark of PDS Biotechnology Corporation.<\/p>\n

\n Investor Contact:<\/strong>
\n
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Jude Gorman \/ Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The amendment includes PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and\/or metastatic head and neck cancer. Median overall survival (mOS) remains the trial\u2019s primary endpoint for full approval, consistent with the Company\u2019s prior regulatory dialogue and post-meeting communication following its Type C meeting with the U.S. … <\/p>\n

Continue reading “PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-938698","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The amendment includes PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and\/or metastatic head and neck cancer. Median overall survival (mOS) remains the trial\u2019s primary endpoint for full approval, consistent with the Company\u2019s prior regulatory dialogue and post-meeting communication following its Type C meeting with the U.S. … Continue reading "PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T14:26:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval\",\"datePublished\":\"2026-02-20T14:26:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/\",\"name\":\"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=\",\"datePublished\":\"2026-02-20T14:26:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Market Newsdesk","og_description":"Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The amendment includes PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and\/or metastatic head and neck cancer. Median overall survival (mOS) remains the trial\u2019s primary endpoint for full approval, consistent with the Company\u2019s prior regulatory dialogue and post-meeting communication following its Type C meeting with the U.S. … Continue reading \"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-20T14:26:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval","datePublished":"2026-02-20T14:26:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/"},"wordCount":1093,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/","name":"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=","datePublished":"2026-02-20T14:26:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1Nzg4NyM3NDM1MTE2IzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-adoption-of-amended-protocol-for-phase-3-versatile-003-trial-incorporating-progression-free-survival-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-appr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=938698"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=938698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=938698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=938698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}